{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-006171","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.251015+00:00","generated_at":"2026-05-17T13:08:07.412355+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort","bullets":["Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.","PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.","July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.","R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-006171","json":"https://secwatch.observer/filing/0001683168-25-006171.json","markdown":"https://secwatch.observer/filing/0001683168-25-006171.md","text":"https://secwatch.observer/filing/0001683168-25-006171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/0001683168-25-006171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:08:07.412355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}